These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 20687620)
1. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Carter NJ; Keating GM Drugs; 2010 Aug; 70(12):1545-77. PubMed ID: 20687620 [TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. Simpson D; Noble S; Perry C CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116 [TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Scott LJ CNS Drugs; 2013 Nov; 27(11):971-88. PubMed ID: 24129744 [TBL] [Abstract][Full Text] [Related]
4. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877 [TBL] [Abstract][Full Text] [Related]
5. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis. Simpson D; Noble S; Perry C BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757 [TBL] [Abstract][Full Text] [Related]
6. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
8. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992 [TBL] [Abstract][Full Text] [Related]
9. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis. Sanford M; Lyseng-Williamson KA Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977 [TBL] [Abstract][Full Text] [Related]
11. Interferon-β-1b: a review of its use in multiple sclerosis. Plosker GL CNS Drugs; 2011 Jan; 25(1):67-88. PubMed ID: 21128695 [TBL] [Abstract][Full Text] [Related]
12. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. Johnston J; So TY Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799 [TBL] [Abstract][Full Text] [Related]
13. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M; Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268 [TBL] [Abstract][Full Text] [Related]
14. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454 [TBL] [Abstract][Full Text] [Related]
15. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
16. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
17. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Wolinsky JS; Narayana PA; Johnson KP; Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192 [TBL] [Abstract][Full Text] [Related]
18. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320 [TBL] [Abstract][Full Text] [Related]
20. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. Flechter S; Vardi J; Pollak L; Rabey JM J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]